Skip to main content
In stock | Targeted Therapy

APG-2575 (Lisaftoclax)

Oncology Type Hematologic
Drug Class / Mechanism BCL-2 Inhibitor
No Image
Description

APG-2575 (Lisaftoclax) is classified as a BCL-2 Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Hematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3